News Releases

Aug 30, 2023	Pulmonx to Participate at Upcoming Investor Conferences REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences.
Aug 02, 2023	Pulmonx Reports Second Quarter 2023 Financial Results REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023.
Jul 26, 2023	Pulmonx to Present at the Canaccord Genuity 43rd Annual Growth Conference REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 43 rd Annual Growth Conference in Boston.
Jul 17, 2023	Pulmonx to Report Second Quarter 2023 Financial Results on August 2, 2023 REDWOOD CITY, Calif. , July 17, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2023 after the close of trading on Wednesday,
May 02, 2023	Pulmonx Reports First Quarter 2023 Financial Results REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2023 ended March 31, 2023.
Apr 25, 2023	Pulmonx to Present at the Bank of America Securities 2023 Health Care Conference REDWOOD CITY, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2023 Health Care Conference in Las Vegas
Apr 18, 2023	Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023 REDWOOD CITY, Calif. --(BUSINESS WIRE)--Apr. 18, 2023-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Tuesday, May
Feb 22, 2023	Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2022 ended December 31, 2022.
Feb 16, 2023	Pulmonx to Present at the Citi 2023 Healthcare Conference REDWOOD CITY, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2023 Healthcare Conference in New York on
Feb 08, 2023	Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading

Print Page

Email Alerts

Contact IR

RSS Feeds